CliffBio
biologic

Phesgo

pertuzumab, trastuzumab, and hyaluronidase-zzxf

Loss of exclusivityJune 2032projected — 12-year biologic exclusivity estimate
CompanyGenentech →See this company's full patent-cliff portfolio

Drug detail

Brand namePhesgo
Active ingredientpertuzumab, trastuzumab, and hyaluronidase-zzxf
Strength600MG, 600MG, 20,000UNITS/10ML (60MG, 60MG, 2,000UNITS/ML)
Dosage formInjection
RouteSubcutaneous
ModalityBiologic
FDA approvalJune 2020
Marketing statusRx

More from Genentech

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.